UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 29, 2010
Momenta Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
|
000-50797 |
|
04-3561634 |
|
(State or Other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
675 West Kendall Street, Cambridge, MA |
|
02142 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
(617) 491-9700
(Registrant’s telephone number,
including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 - Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers
(e)
On July 29, 2010, the Compensation Committee of the Board of Directors of Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), approved the following incentive cash bonuses to the executive officers of the Company listed below as part of a Company-wide recognition of the approval by the U.S. Food and Drug Administration of the abbreviated new drug application filed for enoxaparin sodium injection, a generic version of Lovenox®:
|
Name |
|
Bonus |
|
|
|
Craig A. Wheeler |
|
$ |
131,764 |
|
|
|
|
|
|
|
|
Richard P. Shea |
|
$ |
42,315 |
|
|
|
|
|
|
|
|
Steven B. Brugger |
|
$ |
68,911 |
|
|
|
|
|
|
|
|
John E. Bishop, Ph.D. |
|
$ |
42,869 |
|
|
|
|
|
|
|
|
James Roach |
|
$ |
49,730 |
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MOMENTA PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
|
|
Date: July 29, 2010 |
By: |
/s/ Richard P. Shea |
|
|
|
|
|
|
|
Richard P. Shea Chief Financial Officer (Principal Financial Officer) |